Delcath Systems (NASDAQ:DCTH) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Delcath Systems (NASDAQ:DCTH) in a report issued on Friday morning, Marketbeat Ratings reports. They currently have a $22.00 price objective on the stock.

Several other equities research analysts have also recently weighed in on DCTH. StockNews.com cut Delcath Systems from a “hold” rating to a “sell” rating in a research note on Thursday. Craig Hallum initiated coverage on Delcath Systems in a research report on Friday, June 28th. They set a “buy” rating and a $18.00 target price on the stock. Finally, Stephens restated an “overweight” rating and issued a $25.00 price target on shares of Delcath Systems in a research report on Tuesday, August 6th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Delcath Systems presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.50.

Delcath Systems Trading Up 10.3 %

Shares of DCTH stock opened at $11.28 on Friday. The stock’s 50-day moving average price is $9.12 and its 200-day moving average price is $7.71. Delcath Systems has a 12-month low of $2.25 and a 12-month high of $11.74. The stock has a market capitalization of $313.43 million, a price-to-earnings ratio of -4.26 and a beta of 0.78.

Delcath Systems (NASDAQ:DCTH) last posted its earnings results on Monday, August 5th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.12). Delcath Systems had a negative net margin of 474.22% and a negative return on equity of 312.48%. The business had revenue of $7.77 million during the quarter, compared to analysts’ expectations of $5.00 million. During the same period last year, the business posted ($0.58) earnings per share. As a group, research analysts predict that Delcath Systems will post -1.67 EPS for the current fiscal year.

Institutional Trading of Delcath Systems

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Delcath Systems by 31.0% during the 1st quarter. Vanguard Group Inc. now owns 683,686 shares of the company’s stock valued at $3,261,000 after buying an additional 161,678 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Delcath Systems during the second quarter valued at approximately $694,000. Shellback Capital LP purchased a new stake in shares of Delcath Systems in the second quarter valued at approximately $1,353,000. Cubist Systematic Strategies LLC bought a new position in Delcath Systems in the second quarter worth approximately $370,000. Finally, Legato Capital Management LLC purchased a new position in Delcath Systems during the 2nd quarter worth $966,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.